DRUG DISCOVERY AND DEVELOPMENT 21
world-class healthcare solutions in China. We are glad to be partnering with Hisun in this venture to address the needs of our patients.”
Te production plants of the joint venture will be located in Fuyang, Zhejiang province, while the management centre and R&D centre will be located in Shanghai and Hangzhou, respectively. Te parties will contribute select existing products to the joint venture, which will have a broad portfolio covering cardiovascular disease, infectious disease, oncology, mental health, and other therapeutic areas.
“We are confident that our joint venture will allow both companies to build upon existing core capabilities and our respective areas of expertise to address the needs of more patients than ever before,” adds Olivier Brandicourt, president and general manager of Pfizer’s emerging markets and established products business units. “Tis partnership further supports the government of China’s goals for improved access to medicines and treatments for the patients of China.”
Dermo-cosmetics Quintiles and Sinclair IS Pharma have signed a 10-year collaboration and licensing agreement for Quintiles Rowfarma Mexico to commercialise Sinclair’s portfolio of dermo-cosmetic products and medical devices in Mexico.
Under the agreement, Quintiles will handle the entire process including: regulatory submissions; product importation, warehousing and distribution to wholesalers; sales force promotion to dermatologists and plastic surgeons; and marketing, advertising and promotion.
“Tis collaboration, a further step in Latin America, supports our company’s growth strategy, to move our product portfolio into fast- growing, emerging markets through strategic, regional partnerships,” said Chris Spooner, ceo Sinclair IS Pharma. “Quintiles’ extensive commercialisation experience and proven track record in Mexico and other emerging markets made it the clear choice to help us execute our strategy.”
Te Sinclair portfolio consists of the following products: Atopiclair for the treatment of mild to moderate atopic dermatitis; Kelo-cote silicone-gel scar reduction range for the prevention and management of abnormal scars; Sebclair for the treatment of seborrhoeic dermatitis; Bio-Taches for hyperpigmentation disorders; XClair for the treatment of radiation dermatitis; and Papulex for the management and maintenance of mild to moderate acne.
“Our customers are thinking carefully about their strategy in emerging markets, and are looking for a trusted partner who can
help navigate the complexities these markets present. With this agreement, Quintiles’ will work on a wide range of services – from registration through to launch, to help Sinclair expand its geographic footprint in a more predictable manner,” said company senior vice president of commercial strategy James Featherstone.
Cristobal Tompson, country manager for Quintiles Commercial Solutions in Mexico, added: “We look forward to working with Sinclair to commercialise these promising products in Mexico, a market that offers significant business opportunities. With our 16-year heritage in Mexico, our local market experience will complement Quintiles global systems and standards, to help accelerate outcomes for Sinclair.”
Meanwhile EMD Millipore, the life science division of Merck KGaA, has opened its advanced GMP bioproduction facility in Martillac, France, offering a full, single-use process train to speed a molecule’s journey to the clinic (Fig. 1).
Te site will serve users of EMD Millipore’s Provantage biodevelopment and clinical supply solutions, an innovative, ‘open source’ manufacturing option that incorporates the latest technologies for upstream and downstream processes.
Non-profit tie-up to speed up drug development T
en major global drug firms have teamed up to establish and fund a non-profit organisation focused on ultimately speeding
drug development by addressing a range of existing challenges. Slated as the largest ever initiative of its kind, TransCelerate Biopharma will initially target issues in clinical study execution. The organisation’s founding partners are: Abbott,
AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche’s Genentech, and Sanofi. Each will combine financial and other resources, including personnel, and have agreed specific outcome-orientated objectives and
guidelines for sharing data and expertise. Five clinical trials-related projects have
been for initial funding and development. These include: development of a shared-user interface for investigator site portals; mutual recognition of study-site qualification and training; development of risk-based site monitoring approach and standards; development of clinical data standards; and establishment of a comparator drug supply model. The firms say that as solutions in clinical research
and other areas are developed it will draw in other relevant industry alliances and regulatory bodies, including the Clinical Data Interchange Standards
Consortium (CDISC), Critical-Path Institute (C-Path), the Clinical Trials Transformation Initiative (CTT), Inovative Medicines Initiative (IMI), FDA, and the European Medicines Agency (EMA), as well as contract research organisations. TransCelerate is headed by ceo Garry Neil, a
partner at Apple Tree Partners and formerly corporate vp for science and technology at Johnson & Johnson. “There is widespread alignment among the heads of R&D at major pharmaceutical companies that there is a critical need to substantially increase the number of innovative new medicines, while eliminating inefficiencies that drive up R&D costs,” he said.
www.scientistlive.com
Te open source approach provides customers with greater control over production. With a traditional outsourcing model, the customer’s process must fit the facility and the contract manufacturer controls the process. With ProVantage solutions, EMD Millipore develops the process for further use by the customer.
At the new facility, EMD Millipore provides access to proven technologies, process development expertise and validation services, offering a robust template that makes it possible to go from clone selection to GMP product in only 12 months. Te facility offers GMP production of mammalian proteins for pre- clinical to phase II production at the 50-1250 litre scale. For phase III and commercial production, customers can transfer manufacturing to any location, at any scale. Tis freedom brings enhances development and manufacturing.
“EMD Millipore leverages more than 25 years of biomanufacturing experience with 150 molecules in our new facility in France,” said Christophe Couturier, vice president of services and solutions, EMD Millipore. “As the basis for Provantage solutions, our experts complement customers’ internal capabilities in a way that combines the best of in-house production and conventional outsourcing. Te end result is increased productivity and an accelerated time to market.”
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52